In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417

K. Shiota, K. Yoshida, C. Noguchi, R. Nakayama

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, γ-butyrolactone - γ-carbonyl - L - histidyl - L - prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion. Static incubations of the cells with different concentrations of DN-1417 (10-7 - 10-4 M) and TRH (10-10 - 10-6 M) resulted in a dose-related increase of TSH release and the response to both peptides, in logarithmic doses, was in parallel. The potency of DN-1417 related to TSH release was 0.14 - 0.26% that of TRH. Maximal TSH release induced by DN-1417 (10-5 M) was slightly but significantly greater than that of TRH (10-7 M). In the presence of 3-isobutyl-1-methylxanthine, the TSH response to either of the peptides was augmented, and the difference in the maximal TSH release by either peptide became significant, suggesting that TRH as well as DN-1417 act through the same mechanism of mediation by the cyclic nucleotides. In the superfusion study, a biphasic profile of TSH release was observed during a continuous exposure (100 min) to maximal doses of either the analogue or TRH. The biphasic release of TSH was thought to be specific to TRH action because high K+ produced a different profile of the release. These results indicate that the potency of DN-1417 in TSH release is considerably lower than that of TRH, and also suggest that the direct action of DN-1417 on TSH release is qualitatively similar to that of TRH.

Original languageEnglish
Pages (from-to)71-78
Number of pages8
JournalActa Endocrinologica
Volume106
Issue number1
Publication statusPublished - 1984
Externally publishedYes

Fingerprint

Thyrotropin
Hormones
Peptides
DN 1417
In Vitro Techniques
1-Methyl-3-isobutylxanthine
Cyclic Nucleotides
Pituitary Gland
Cultured Cells
Central Nervous System

ASJC Scopus subject areas

  • Endocrinology

Cite this

Shiota, K., Yoshida, K., Noguchi, C., & Nakayama, R. (1984). In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417. Acta Endocrinologica, 106(1), 71-78.

In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417. / Shiota, K.; Yoshida, K.; Noguchi, C.; Nakayama, R.

In: Acta Endocrinologica, Vol. 106, No. 1, 1984, p. 71-78.

Research output: Contribution to journalArticle

Shiota, K, Yoshida, K, Noguchi, C & Nakayama, R 1984, 'In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417', Acta Endocrinologica, vol. 106, no. 1, pp. 71-78.
Shiota, K. ; Yoshida, K. ; Noguchi, C. ; Nakayama, R. / In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417. In: Acta Endocrinologica. 1984 ; Vol. 106, No. 1. pp. 71-78.
@article{106825a6878e49639bf6133505cfb281,
title = "In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417",
abstract = "Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, γ-butyrolactone - γ-carbonyl - L - histidyl - L - prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion. Static incubations of the cells with different concentrations of DN-1417 (10-7 - 10-4 M) and TRH (10-10 - 10-6 M) resulted in a dose-related increase of TSH release and the response to both peptides, in logarithmic doses, was in parallel. The potency of DN-1417 related to TSH release was 0.14 - 0.26{\%} that of TRH. Maximal TSH release induced by DN-1417 (10-5 M) was slightly but significantly greater than that of TRH (10-7 M). In the presence of 3-isobutyl-1-methylxanthine, the TSH response to either of the peptides was augmented, and the difference in the maximal TSH release by either peptide became significant, suggesting that TRH as well as DN-1417 act through the same mechanism of mediation by the cyclic nucleotides. In the superfusion study, a biphasic profile of TSH release was observed during a continuous exposure (100 min) to maximal doses of either the analogue or TRH. The biphasic release of TSH was thought to be specific to TRH action because high K+ produced a different profile of the release. These results indicate that the potency of DN-1417 in TSH release is considerably lower than that of TRH, and also suggest that the direct action of DN-1417 on TSH release is qualitatively similar to that of TRH.",
author = "K. Shiota and K. Yoshida and C. Noguchi and R. Nakayama",
year = "1984",
language = "English",
volume = "106",
pages = "71--78",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - In vitro thyrotrophin release with thyrotrophin-releasing hormone and an analogue, DN-1417

AU - Shiota, K.

AU - Yoshida, K.

AU - Noguchi, C.

AU - Nakayama, R.

PY - 1984

Y1 - 1984

N2 - Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, γ-butyrolactone - γ-carbonyl - L - histidyl - L - prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion. Static incubations of the cells with different concentrations of DN-1417 (10-7 - 10-4 M) and TRH (10-10 - 10-6 M) resulted in a dose-related increase of TSH release and the response to both peptides, in logarithmic doses, was in parallel. The potency of DN-1417 related to TSH release was 0.14 - 0.26% that of TRH. Maximal TSH release induced by DN-1417 (10-5 M) was slightly but significantly greater than that of TRH (10-7 M). In the presence of 3-isobutyl-1-methylxanthine, the TSH response to either of the peptides was augmented, and the difference in the maximal TSH release by either peptide became significant, suggesting that TRH as well as DN-1417 act through the same mechanism of mediation by the cyclic nucleotides. In the superfusion study, a biphasic profile of TSH release was observed during a continuous exposure (100 min) to maximal doses of either the analogue or TRH. The biphasic release of TSH was thought to be specific to TRH action because high K+ produced a different profile of the release. These results indicate that the potency of DN-1417 in TSH release is considerably lower than that of TRH, and also suggest that the direct action of DN-1417 on TSH release is qualitatively similar to that of TRH.

AB - Using dispersed and primarily cultured cells of rat pituitary glands, thyrotrophin (TSH) release by TSH-releasing hormone (TRH) and an analogue, γ-butyrolactone - γ-carbonyl - L - histidyl - L - prolinamide (DN-1417) which is more potent than TRH on central nervous system behavioural paradigms, was examined under conditions of static incubation and superfusion. Static incubations of the cells with different concentrations of DN-1417 (10-7 - 10-4 M) and TRH (10-10 - 10-6 M) resulted in a dose-related increase of TSH release and the response to both peptides, in logarithmic doses, was in parallel. The potency of DN-1417 related to TSH release was 0.14 - 0.26% that of TRH. Maximal TSH release induced by DN-1417 (10-5 M) was slightly but significantly greater than that of TRH (10-7 M). In the presence of 3-isobutyl-1-methylxanthine, the TSH response to either of the peptides was augmented, and the difference in the maximal TSH release by either peptide became significant, suggesting that TRH as well as DN-1417 act through the same mechanism of mediation by the cyclic nucleotides. In the superfusion study, a biphasic profile of TSH release was observed during a continuous exposure (100 min) to maximal doses of either the analogue or TRH. The biphasic release of TSH was thought to be specific to TRH action because high K+ produced a different profile of the release. These results indicate that the potency of DN-1417 in TSH release is considerably lower than that of TRH, and also suggest that the direct action of DN-1417 on TSH release is qualitatively similar to that of TRH.

UR - http://www.scopus.com/inward/record.url?scp=0021245901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021245901&partnerID=8YFLogxK

M3 - Article

C2 - 6428117

AN - SCOPUS:0021245901

VL - 106

SP - 71

EP - 78

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -